SEASTAR MEDICAL HOLDING CORPORATION SeaStar Medical Holding Corporation announced the publication of a case series of three critically ill children with Shiga-toxin-associated hemolytic uremic syndrome (STEC-HUS), a severe cause of acute kidney injury (AKI), who were safely treated with SeaStar Medical's Selective Cytopheretic Device for children (SCD-PED). All three children were in the ICU at two different hospitals and treated with continuous kidney replacement therapy (CKRT). Each show gradual improvement following treatment with the SCD-PED and normalization or near normalization of kidney function at 60-day follow up.
The article, "Hemolytic Uremic Syndrome-Induced Acute Kidney Injury Treated via Immunomodulation with the Selective CytopheretIC Device: Cases of STEC-HUS Treated with Immunomodulation via SCD CRRT Filter, (H. Rhodes Hambrick, et al.) was published in the peer-reviewed journal Blood Purification.
